FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 505 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Newly Developed International Childhood Cancer Core Outcome Set Represents Physical, Psychosocial,... July 11, 2023 ESMO Welcomes the WHO Global Status Report on Cancer with Key... July 15, 2026 To Combat Cancer Treatment Resistance, Researchers Try Leveraging Evolution August 22, 2024 EMA Recommends Extension of Therapeutic Indications for Irinotecan Hydrochloride Trihydrate April 3, 2024 Load more HOT NEWS No Benefit of Additional Tumour Testing in HER2-negative Metastatic Breast Cancer... Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over... Talk Cancer: How to have conversations that could save lives Family Brings Joy & Raises Money With Their Extravagant Christmas Light...
